Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
- None.
- None.
Insights
The collaboration between Exact Sciences and Mayo Clinic represents a significant step in the integration of personalized medicine into clinical practice. The focus on comprehensive genomic profiling and hereditary cancer tests is indicative of a broader trend in oncology to tailor treatments based on individual genetic information. By expanding the data available for analysis, researchers can better understand the genetic underpinnings of cancer, which could lead to the development of more effective, targeted therapies.
This initiative has the potential to improve patient outcomes, as treatments can be more accurately matched to the genetic profile of a patient's cancer. From a business perspective, this collaboration could position Exact Sciences favorably within the precision medicine market, potentially increasing demand for their testing services. However, the costs associated with expanding these services and the need for continuous investment in research and development must be weighed against the expected revenue growth.
Exact Sciences' partnership with a prestigious institution like Mayo Clinic may enhance its credibility and visibility in the market. The initiative could lead to an increase in the company's market share in the cancer diagnostics sector, which is a key growth area in healthcare. As precision medicine becomes more prevalent, insurance companies and healthcare providers may be more inclined to adopt these advanced testing methods, potentially leading to increased insurance coverage and broader test utilization.
It is important to monitor the adoption rate of these tests and the impact on the company's financial performance. The success of this initiative could also spur further collaborations with other healthcare institutions, enhancing Exact Sciences' strategic positioning. However, competition from other biotech firms investing in similar technologies could pose a challenge and should be considered in the analysis of the company's market prospects.
The strategic alliance with Mayo Clinic may serve as a catalyst for Exact Sciences' stock performance, depending on how the market perceives the potential for future revenue streams from this initiative. Investors will be interested in the scalability of this service and the company's ability to leverage the data collected to drive innovation and maintain a competitive edge.
While the immediate financial impact may be limited, the long-term implications for growth could be substantial. It will be important to assess the initiative's contribution to the company's top-line growth and margins over time. Moreover, the market will likely scrutinize the company's quarterly earnings reports for indications of the initiative's success and its effect on overall profitability.
Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center
Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
“This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy, chairman and chief executive officer, Exact Sciences. “By combining the strength of Exact Sciences' portfolio of tests with Mayo Clinic's world-renowned medical and scientific expertise, we'll help put cancer patients on a path to potentially more effective, targeted therapies and better outcomes.”
Specialists at Mayo Clinic Comprehensive Cancer Center care for more than 130,000 unique cancer patients each year at three Mayo Clinic Comprehensive Cancer Center sites across
The OncoExTra test—a comprehensive DNA and RNA-based genomic test—provides doctors and their patients with a comprehensive molecular picture of the patient’s cancer. The test’s clinical report includes actionable results personalized to each patient. The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
“Having access to comprehensive genomic sequencing, using whole exome and transcriptome sequencing for the patients we serve across
“This comprehensive sequencing data will also be integrated into the development of large language models (LLMs) and multi-modal artificial intelligence (AI) algorithms to predict cancer risk, detect cancers earlier, and guide intervention. Integration of this genomic data into our longitudinal patient healthcare records in Mayo Clinic Cloud and Mayo Clinic Platform, will facilitate not only the care of each individual patient, but the care of all cancer patients now and in the future,” Dr. Willman added. “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine.”
Patients will consent to have the tests performed and to have the data shared with Mayo Clinic. They will also receive copies of the results for their personal record keeping.
Exact Sciences offers patients and their health care providers access to molecular and genomic data that may provide new insights into the causes of cancers and help researchers develop more effective, personalized treatments for cancer patients.
About Exact Sciences’ Precision Oncology portfolio
Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX Breast Recurrence Score test is recognized as a standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive test of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive molecular tests available to patients today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. The Oncotype DX Breast Recurrence Score test and OncoExTra test were developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory and the OncoExTra test is performed at the Genomic Health Phoenix clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. These tests have not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. To learn more, visit precisiononcology.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
NOTE: Oncotype, Oncotype DX Breast Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard and Riskguard are trademarks of Exact Sciences Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404198461/en/
Media (
Gisela Pedroza
+1 949-468-7854
gpedroza@exactsciences.com
Media (OUS):
Federico Maiardi
+41 79-138-1326
fmaiardi@exactsciences.com
Investors:
Nathan Harrill
+1 608-535-8659
investorrelations@exactsciences.com
Source: Exact Sciences Corp.
FAQ
What is Exact Sciences' ticker symbol?
What is the initiative launched by Exact Sciences with Mayo Clinic?
How does the collaboration between Exact Sciences and Mayo Clinic benefit cancer research?
What is the goal of the collaboration between Exact Sciences and Mayo Clinic?
